-

$undefined

N/A

(N/A)

Mustang Bio Inc NASDAQ:MBIO Mustang Bio, Inc. ("Mustang") is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission ("SEC").

Location: 2 Gansevoort St Fl 9, New York, 10014-1667, United States | Website: www.mustangbio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-1.93M

Cash

6.839M

Avg Qtr Burn

-2.853M

Short % of Float

2.69%

Insider Ownership

12.67%

Institutional Own.

3.77%

Qtr Updated

12/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
MB-207 Details X-Linked severe combined immunodeficiency, Myelofibrosis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MB-107 Details X-Linked severe combined immunodeficiency	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MB-106 (CD20) (Mustang Multicenter) Details Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Cancer, Lymphoma	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MB-106 (CD20) (Fred Hutch) Details Lymphoma, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Epstein-Barr virus, Multiple sclerosis, Cancer, Waldenstrom macroglobulinemia	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MB-101 (IL-13Ra2) + MB-108 Details Medulloblastoma, Ependymoma, Glioblastoma, Leptomeningeal brain tumors	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MB-102 (CD123) Details High risk myelodysplastic syndromes , Blastic plasmacytoid dendritic cell neoplasm, Acute myeloid leukemia, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MB-103 (HER2) Details Glioblastoma, Metastatic breast cancer to brain, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MB-104 Details Multiple myeloma, Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MB-105 (PSCA) Details Prostate cancer, Multiple myeloma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MB-110 (LV-RAG1) Details Severe combined immunodeficiency due to complete RAG1/2 deficiency	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.